Therapy & companion diagnostics ↗
Both involve Guardant Health, but screening and treatment selection are distinct uses and markets.
Evidence: Guardant Health ↗FDA ↗
Commercialization · TOPIC v4
Can Shield Bring More People into Colorectal Cancer Screening?
How far will broader coverage translate into new screening and diagnostic follow-up?
Read article → Can Shield Bring More People into Colorectal Cancer Screening?
Read article → Shield: Can Expanded Coverage Lead to Screening and Diagnosis?
2026-09-23 09:45:04.320 UTC · Last recorded update
CURRENT READING
Guardant announced Shield’s inclusion in EviCore guidelines, effective January 1, 2027. This is not an update to detection performance.
Recorded editorial state, not a maturity score
- Policy announcementRecorded
- January 2027 implementationScheduled
- Testing and paymentUnverified
- Follow-up colonoscopyUnverified
Additional source checked · v3 → 4
Added planned EviCore implementation; prior clinical-performance assessment is unchanged.
Permanent link to this revision ↗01 / WHAT WE TRACK
How far will broader coverage translate into new screening and diagnostic follow-up?
02 / EVIDENCE & TECHNOLOGY
Blood-based colorectal cancer screening / coverage / diagnostic follow-up
03 / EDITORIAL READING
How far will broader coverage translate into new screening and diagnostic follow-up?
04 / WHAT REMAINS UNKNOWN
A planned change reported by the company. The underlying policy and individual plan conditions have not been independently checked; this does not establish unconditional coverage or increased revenue.
05 / NEXT CHECK
Track implementation, tests and payments, participation by previously unscreened people, and completed follow-up colonoscopies separately.
tests / quarter (company-reported, approximate)
2025 Q216,000
2026 Q266,000
Two same-quarter observations a year apart; the path between them is unknown. This does not measure the effect of the September Carelon announcement. Ratio calculated from rounded disclosures.
Sources: Guardant Health ↗A hypothesis to keep honest
HYPOTHESIS · NOT YET TESTEDBroader coverage combined with follow-up support may increase the number reaching diagnosis, not just the number tested.
What would change our view: Reconsider if wider eligibility does not increase new screening or completed follow-up colonoscopies.
A prospective test proposal, not a prediction score. A graph connection does not validate this hypothesis.
Linked people & organizations
Open an entity to find its cardsCOMPANYGuardant Health ↗
Provider of Shield and Guardant360 CDx; distinct products and uses.
Evidence: Guardant Health ↗FDA ↗
COMPANYCarelon Health Services ↗
Named in coverage announcement; policy text not independently checked.
Evidence: Guardant Health ↗
Related questions, optional follows
Map ↗Signatera: Using Tumor DNA in Blood to Guide Treatment After Surgery ↗
Compares screening follow-up with postoperative treatment selection, not test performance.
Latest card updates
Latest 5 · editorial record dates- v4 · 2026-09-23 09:45:04.320 UTCAdditional source checked
Added planned EviCore implementation; prior clinical-performance assessment is unchanged.
Reading at the time: Guardant announced Shield’s inclusion in EviCore guidelines, effective January 1, 2027. This is not an update to detection performance.
- v3 · 2026-09-07 11:00:45.083 UTCAdditional source checked
Updated the related analysis after further source checks. This is not a newly announced trial or experiment.
Reading at the time: Testing and revenue have grown. Track previously unscreened participants, diagnostic follow-up and assay improvements separately.
Earlier updates (0)
Earlier entries will appear here once more than five reader-facing revisions have accumulated.
Source-event timeline (different from editorial revisions)
- Recorded event
FDA approval date, distinct from the issuer announcement.
Sources: FDA ↗ - Recorded event
Q2 2026 test volumes disclosed by the company.
Sources: Guardant Health ↗ - Recorded event
Carelon coverage announced by the company.
Sources: Guardant Health ↗ - Scheduled
Announced effective date; implementation not yet confirmed.
Sources: Guardant Health ↗ - Recorded event
Guardant announced Shield’s inclusion in EviCore guidelines, effective January 1, 2027. This is not an update to detection performance.
Sources: investors.guardanthealth.com ↗ - Scheduled
Scheduled effective date for EviCore guidelines.
Sources: investors.guardanthealth.com ↗
Historical events were assembled through source research. They do not imply the magazine tracked them at the time.
Background readings
Commercialization
Can Shield Bring More People into Colorectal Cancer Screening?
Who will a blood draw bring into screening? Costs in Japan and a growing testing business in the US.
Commercialization
Shield: Can Expanded Coverage Lead to Screening and Diagnosis?
Following a coverage-policy change through screening, payment and diagnostic follow-up.
Source dates and verification scope
NEJM原著 ↗
NEJM原著 · checked 2026-09-07 · primary
FDA審査資料 ↗
FDA審査資料 · checked 2026-09-07 · primary
FDA製品情報 ↗
FDA製品情報 · checked 2026-09-07 · primary
NCIの大腸がん検診解説 ↗
NCIの大腸がん検診解説 · checked 2026-09-07 · primary
中央病院の案内 ↗
中央病院の案内 · checked 2026-09-07 · primary
国立病院機構の任意検診案内 ↗
国立病院機構の任意検診案内 · checked 2026-09-07 · primary
国立がん研究センターのガイドライン ↗
国立がん研究センターのガイドライン · checked 2026-09-07 · primary
Second Quarter 2026 Financial Results ↗
Guardant Health · 2026-07-30 · issuer
Guardant Healthの発表 ↗
investors.guardanthealth.com · checked 2026-09-23 · public-source